Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 115 articles:
HTML format
Text format



Single Articles


    June 2019
  1. CHEN J, Haanpaa MK, Gruber JJ, Jager N, et al
    High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.
    Clin Cancer Res. 2019 Jun 7. pii: 1078-0432.CCR-18-2423.
    PubMed     Text format     Abstract available


    May 2019
  2. MAGBANUA MJM, Yau C, Wolf DM, Lee JS, et al
    Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bone marrow predict adverse outcome in early breast cancer.
    Clin Cancer Res. 2019 May 29. pii: 1078-0432.CCR-18-3888.
    PubMed     Text format     Abstract available


  3. LI Q, Guan X, Chen S, Yi Z, et al
    Safety, Efficacy and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Clin Cancer Res. 2019 May 28. pii: 1078-0432.CCR-18-4173.
    PubMed     Text format     Abstract available


  4. STEENBRUGGEN TG, van Seijen M, Janssen LM, van Ramshorst MS, et al
    Prognostic value of residual disease after neoadjuvant therapy in HER2+ breast cancer evaluated by Residual Cancer Burden, Neoadjuvant Response Index & Neo-Bioscore.
    Clin Cancer Res. 2019 May 10. pii: 1078-0432.CCR-19-0560.
    PubMed     Text format     Abstract available


  5. FILIPITS M, Dubsky P, Rudas M, Greil R, et al
    Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
    Clin Cancer Res. 2019 May 7. pii: 1078-0432.CCR-19-0376.
    PubMed     Text format     Abstract available


  6. MOLINA-CRESPO A, Cadete A, Sarrio D, Gamez-Chiachio M, et al
    Intracellular delivery of an antibody targeting Gasdermin-B reduces HER2 breast cancer aggressiveness.
    Clin Cancer Res. 2019 May 7. pii: 1078-0432.CCR-18-2381.
    PubMed     Text format     Abstract available


  7. WAKS AG, Stover DG, Guerriero JL, Dillon DA, et al
    The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy.
    Clin Cancer Res. 2019 May 6. pii: 1078-0432.CCR-19-0173.
    PubMed     Text format     Abstract available


  8. MEIJER TG, Verkaik NS, Sieuwerts AM, van Riet J, et al
    Correction: Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.
    Clin Cancer Res. 2019;25:2935.
    PubMed     Text format    


    April 2019
  9. MITTENDORF EA, Lu B, Melisko M, Price Hiller J, et al
    Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.
    Clin Cancer Res. 2019 Apr 29. pii: 1078-0432.CCR-18-2867.
    PubMed     Text format     Abstract available


  10. LIGIBEL J, Dillon DA, Giobbie-Hurder A, McTiernan A, et al
    Impact of a pre-operative exercise intervention on breast cancer proliferation and gene expression: Results from the Pre-Operative Health and Body (PreHAB) Study.
    Clin Cancer Res. 2019 Apr 24. pii: 1078-0432.CCR-18-3143.
    PubMed     Text format     Abstract available


  11. ZHANG J, Chen J, Wo D, Yan H, et al
    LRP6 ectodomain prevents SDF-1/CXCR4-induced breast cancer metastasis to lung.
    Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-3557.
    PubMed     Text format     Abstract available


  12. COOMBES C, Page K, Salari R, Hastings RK, et al
    Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-3663.
    PubMed     Text format     Abstract available


  13. MORIKAWA A, de Stanchina E, Pentsova E, Kemeny MM, et al
    Phase I study of intermittent high dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases.
    Clin Cancer Res. 2019 Apr 15. pii: 1078-0432.CCR-18-3502.
    PubMed     Text format     Abstract available


  14. LOIBL S, Treue D, Budczies J, Weber K, et al
    Mutational diversity and therapy response in breast cancer - a sequencing analysis in the neoadjuvant GeparSepto trial.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3258.
    PubMed     Text format     Abstract available


    March 2019
  15. KRAYA AA, Maxwell KN, Wubbenhorst B, Wenz BM, et al
    Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer.
    Clin Cancer Res. 2019 Mar 26. pii: 1078-0432.CCR-18-0468.
    PubMed     Text format     Abstract available


  16. KETTNER NM, Vijayaraghavan S, Durak MG, Bui T, et al
    Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer.
    Clin Cancer Res. 2019 Mar 13. pii: 1078-0432.CCR-18-3274.
    PubMed     Text format     Abstract available


  17. ROTHE F, Silva MJ, Venet D, Campbell C, et al
    Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial.
    Clin Cancer Res. 2019 Mar 12. pii: 1078-0432.CCR-18-2521.
    PubMed     Text format     Abstract available


  18. SJOBERG E, Meyrath M, Milde L, Herrera M, et al
    A novel ACKR2-dependent role of fibroblast-derived CXCL14 in epithelial-to-mesenchymal transition and metastasis of breast cancer.
    Clin Cancer Res. 2019 Mar 8. pii: 1078-0432.CCR-18-1294.
    PubMed     Text format     Abstract available


  19. LIU Z, Li Z, Qu J, Zhang R, et al
    Radiomics of multi-parametric MRI for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study.
    Clin Cancer Res. 2019 Mar 6. pii: 1078-0432.CCR-18-3190.
    PubMed     Text format     Abstract available


  20. XIAO Y, Ma D, Zhao S, Suo C, et al
    Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer.
    Clin Cancer Res. 2019 Mar 5. pii: 1078-0432.CCR-18-3524.
    PubMed     Text format     Abstract available


    February 2019
  21. DI COSIMO S, Appierto V, Pizzamiglio S, Tiberio P, et al
    Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from the NeoALTTO trial.
    Clin Cancer Res. 2019 Feb 27. pii: 1078-0432.CCR-18-2507.
    PubMed     Text format     Abstract available


  22. CHUMSRI S, Serie DJ, Li Z, Pogue-Geile KL, et al
    Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-2206.
    PubMed     Text format     Abstract available


  23. IPPEN FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, et al
    The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3049.
    PubMed     Text format     Abstract available


  24. LOI S, Dushyanthen S, Beavis PA, Salgado R, et al
    Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2019;25:1437.
    PubMed     Text format    


  25. FORMISANO L, Stauffer KM, Young CD, Bhola NE, et al
    Correction: Association of FGFR1 with ERalpha Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER(+) Breast Cancer.
    Clin Cancer Res. 2019;25:1433.
    PubMed     Text format    


  26. UNNI N, Sudhan DR, Arteaga CL
    Correction: Neratinib: Inching Up on the Cure Rate of HER2(+) Breast Cancer?
    Clin Cancer Res. 2019;25:1430.
    PubMed     Text format    


  27. IIZUKA A, Nonomura C, Ashizawa T, Kondou R, et al
    A T-cell-engaging B7-H4/CD3 bispecific Fab-scFv antibody targets human breast cancer.
    Clin Cancer Res. 2019 Feb 8. pii: 1078-0432.CCR-17-3123.
    PubMed     Text format     Abstract available


  28. ZINGER L, Merenbakh-Lamin K, Klein Goldberg A, Elazar A, et al
    Ligand binding domain activating mutations of ESR1 rewire cellular metabolism of breast cancer cells.
    Clin Cancer Res. 2019 Feb 7. pii: 1078-0432.CCR-18-1505.
    PubMed     Text format     Abstract available


  29. MAYER IA, Prat A, Egle D, Blau S, et al
    A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
    Clin Cancer Res. 2019 Feb 5. pii: 1078-0432.CCR-18-3160.
    PubMed     Text format     Abstract available


  30. NAKSHATRI H, Kumar B, Burney HN, Cox ML, et al
    Genetic ancestry-dependent differences in breast cancer-induced field defects in the tumor-adjacent normal breast.
    Clin Cancer Res. 2019 Feb 4. pii: 1078-0432.CCR-18-3427.
    PubMed     Text format     Abstract available


    January 2019
  31. ELMI A, Makvandi M, Weng CC, Hou C, et al
    Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [(18)F]FLT and [(18)F]ISO-1 PET/CT.
    Clin Cancer Res. 2019 Jan 28. pii: 1078-0432.CCR-18-2769.
    PubMed     Text format     Abstract available


  32. TULOTTA C, Lefley DV, Freeman K, Gregory WM, et al
    Endogenous production of IL-1B by breast cancer cells drives metastasis and colonisation of the bone microenvironment.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2202.
    PubMed     Text format     Abstract available


  33. BERGEN ES, Berghoff AS, Medjedovic M, Rudas M, et al
    Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases.
    Clin Cancer Res. 2019 Jan 15. pii: 1078-0432.CCR-18-1968.
    PubMed     Text format     Abstract available


  34. CROSBY EJ, Gwin WR, Blackwell K, Marcom PK, et al
    Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study.
    Clin Cancer Res. 2019 Jan 11. pii: 1078-0432.CCR-18-3102.
    PubMed     Text format     Abstract available


  35. CLARK AS, McAndrew NP, Troxel A, Feldman M, et al
    Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer.
    Clin Cancer Res. 2019 Jan 11. pii: 1078-0432.CCR-18-0790.
    PubMed     Text format     Abstract available


    December 2018
  36. HURVITZ SA, O'Shaughnessy J, Mason G, Yardley D, et al
    Central Nervous System Metastasis in Patients With HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From SystHERs.
    Clin Cancer Res. 2018 Dec 28. pii: 1078-0432.CCR-18-2366.
    PubMed     Text format     Abstract available


  37. TURNER NC, Telli ML, Rugo HS, Mailliez A, et al
    A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-1891.
    PubMed     Text format     Abstract available


  38. HWANG KT, Kim J, Jung J, Chang JH, et al
    Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database.
    Clin Cancer Res. 2018 Dec 17. pii: 1078-0432.CCR-18-2782.
    PubMed     Text format     Abstract available


  39. WILSON HE, Rhodes KK, Rodriguez D, Chahal I, et al
    Human breast cancer xenograft model implicates peroxisome proliferator-activated receptor signaling as driver of cancer-induced muscle fatigue.
    Clin Cancer Res. 2018 Dec 17. pii: 1078-0432.CCR-18-1565.
    PubMed     Text format     Abstract available


  40. HOWIE LJ, Scher NS, Amiri-Kordestani L, Zhang L, et al
    FDA Approval Summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer.
    Clin Cancer Res. 2018 Dec 14. pii: 1078-0432.CCR-18-3003.
    PubMed     Text format     Abstract available


  41. MUNTASELL A, Rojo F, Servitja S, Rubio-Perez C, et al
    NK cell infiltrates and HLA class I expression in primary HER2+ breast cancer predict and uncouple pathological response and disease-free survival.
    Clin Cancer Res. 2018 Dec 6. pii: 1078-0432.CCR-18-2365.
    PubMed     Text format     Abstract available


    November 2018
  42. FOIDART P, Yip C, Radermacher J, Lienard M, et al
    Expression of MT4-MMP, EGFR and RB in triple negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy.
    Clin Cancer Res. 2018 Nov 30. pii: 1078-0432.CCR-18-1880.
    PubMed     Text format     Abstract available


  43. SHIINO S, Matsuzaki J, Shimomura A, Kawauchi J, et al
    Serum miRNA-based prediction of axillary lymph node metastasis in breast cancer.
    Clin Cancer Res. 2018 Nov 27. pii: 1078-0432.CCR-18-1414.
    PubMed     Text format     Abstract available


  44. RACHNER TD, Kasimir-Bauer S, Gobel A, Erdmann K, et al
    Prognostic value of RANKL/OPG serum levels and disseminated tumor cells in non-metastatic breast cancer.
    Clin Cancer Res. 2018 Nov 13. pii: 1078-0432.CCR-18-2482.
    PubMed     Text format     Abstract available



  45. Correction: Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
    Clin Cancer Res. 2018;24:5486.
    PubMed     Text format    



  46. Correction: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer.
    Clin Cancer Res. 2018;24:5485.
    PubMed     Text format    


    October 2018
  47. WANG Z, Liu Q, Wilson CL, Easton J, et al
    Polygenic Determinants for Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: The St Jude Lifetime Cohort Study (SJLIFE).
    Clin Cancer Res. 2018 Oct 26. pii: 1078-0432.CCR-18-1775.
    PubMed     Text format     Abstract available


  48. GRELLETY T, Callens C, Richard E, Briaux A, et al
    Enhancing abiraterone acetate efficacy in androgen receptor-positive triple negative breast cancer: Chk1 as a potential target.
    Clin Cancer Res. 2018 Oct 23. pii: 1078-0432.CCR-18-1469.
    PubMed     Text format     Abstract available


  49. VELDWIJK MR, Seibold P, Botma A, Helmbold I, et al
    Association of CD4(+) radiation-induced lymphocyte apoptosis with fibrosis and telangiectasia after radiotherapy in 272 breast cancer patients with >10-year follow-up.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-0777.
    PubMed     Text format     Abstract available


  50. CROESSMANN S, Formisano L, Kinch L, Gonzalez-Ericsson PI, et al
    Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.
    Clin Cancer Res. 2018 Oct 12. pii: 1078-0432.CCR-18-1544.
    PubMed     Text format     Abstract available


  51. ABOUTALIB SS, Mohamed AA, Berg WA, Zuley ML, et al
    Deep Learning to Distinguish Recalled but Benign Mammography Images in Breast Cancer Screening.
    Clin Cancer Res. 2018 Oct 11. pii: 1078-0432.CCR-18-1115.
    PubMed     Text format     Abstract available


    September 2018
  52. THOREK DL, Ku AT, Mitsiades N, Veach D, et al
    Harnessing Androgen-Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.
    Clin Cancer Res. 2018 Sep 25. pii: 1078-0432.CCR-18-1521.
    PubMed     Text format     Abstract available


  53. HENDERSON MC, Silver M, Tran Q, Letsios EE, et al
    A Non-Invasive Blood-Based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment.
    Clin Cancer Res. 2018 Sep 5. pii: 1078-0432.CCR-18-0843.
    PubMed     Text format     Abstract available


  54. CHEN X, Low KH, Alexander A, Jiang Y, et al
    Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-1446.
    PubMed     Text format     Abstract available


    August 2018
  55. GUINDALINI RS, Zheng Y, Abe H, Whitaker K, et al
    Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers.
    Clin Cancer Res. 2018 Aug 28. pii: 1078-0432.CCR-18-0200.
    PubMed     Text format     Abstract available


  56. MEIJER TG, Verkaik NS, Sieuwerts AM, van Riet J, et al
    Functional ex vivo assay reveals homologous recombination deficiency in breast cancer beyond BRCA gene defects.
    Clin Cancer Res. 2018 Aug 23. pii: 1078-0432.CCR-18-0063.
    PubMed     Text format     Abstract available


  57. MENDEZ O, Peg V, Salvans C, Pujals M, et al
    Extracellular HMGA1 promotes tumor Invasion and Metastasis in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2018 Aug 22. pii: 1078-0432.CCR-18-0517.
    PubMed     Text format     Abstract available


  58. TRAN TH, Utama FE, Sato T, Peck AR, et al
    Loss of nuclear localized Parathyroid Hormone-related Protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed Stat5 signaling.
    Clin Cancer Res. 2018 Aug 10. pii: 1078-0432.CCR-17-3280.
    PubMed     Text format     Abstract available


  59. CHEUNG A, Opzoomer JW, Ilieva KM, Gazinska P, et al
    Anti-Folate Receptor alpha-directed Antibody Therapies Restrict the Growth of Triple Negative Breast Cancer.
    Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-0652.
    PubMed     Text format     Abstract available


    July 2018
  60. SHARMA P, Lopez-Tarruella S, Garcia-Saenz JA, Khan QJ, et al
    Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel.
    Clin Cancer Res. 2018 Jul 30. pii: 1078-0432.CCR-18-0585.
    PubMed     Text format     Abstract available


  61. TANIOKA M, Fan C, Parker JS, Hoadley KA, et al
    Integrated analysis of RNA and DNA from a phase III trial of trastuzumab-based neoadjuvant chemotherapy identifies response predictors in HER2-positive breast cancer.
    Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-17-3431.
    PubMed     Text format     Abstract available


  62. GONZALEZ-GONZALEZ A, Munoz-Muela E, Marchal JA, Cara FE, et al
    Activating transcription factor 4 modulates TGFbeta-induced aggressiveness in triple negative breast cancer via SMAD2/3/4 and mTORC2 signaling.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-17-3125.
    PubMed     Text format     Abstract available


    June 2018
  63. SHEN H, Mu C, Wu X, Zhou X, et al
    Chemotherapy sensitizes therapy-resistant cells to mild hyperthermia by suppressing heat shock protein 27 expression in triple negative breast cancer.
    Clin Cancer Res. 2018 Jun 19. pii: 1078-0432.CCR-17-3872.
    PubMed     Text format     Abstract available


  64. CUI Y, Li B, Pollom EL, Horst K, et al
    Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.
    Clin Cancer Res. 2018 Jun 19. pii: 1078-0432.CCR-18-0825.
    PubMed     Text format     Abstract available


  65. PARK H, Lim Y, Ko ES, Cho HH, et al
    Radiomics Signature on Magnetic Resonance Imaging: Association with Disease-Free Survival in Patients with Invasive Breast Cancer.
    Clin Cancer Res. 2018 Jun 18. pii: 1078-0432.CCR-17-3783.
    PubMed     Text format     Abstract available


  66. SHAH D, Wyatt D, Baker A, Simms P, et al
    Inhibition of HER2 Enriches for Jagged1-dependent Breast Cancer Stem Cells: Role for Membrane Jagged1.
    Clin Cancer Res. 2018 Jun 12. pii: 1078-0432.CCR-17-1952.
    PubMed     Text format     Abstract available


  67. BARRY P, Vatsiou A, Spiteri I, Nichol D, et al
    The spatio-temporal evolution of lymph node spread in early breast cancer.
    Clin Cancer Res. 2018 Jun 11. pii: 1078-0432.CCR-17-3374.
    PubMed     Text format     Abstract available


  68. BARDIA A, Hurvitz S
    Targeted therapy for premenopausal women with HR+, HER2- advanced breast cancer: focus on special considerations and latest advances.
    Clin Cancer Res. 2018 Jun 8. pii: 1078-0432.CCR-18-0162.
    PubMed     Text format     Abstract available


    May 2018
  69. UNNI N, Sudhan DR, Arteaga CL
    Neratinib: Inching up on the cure rate of HER2+ breast cancer?
    Clin Cancer Res. 2018 May 25. pii: 1078-0432.CCR-18-1114.
    PubMed     Text format     Abstract available


  70. ANURAG M, Punturi N, Hoog J, Bainbridge MN, et al
    Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers.
    Clin Cancer Res. 2018 May 23. pii: 1078-0432.CCR-17-3702.
    PubMed     Text format     Abstract available


  71. DICKLER MN, Saura C, Richards D, Krop I, et al
    Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
    Clin Cancer Res. 2018 May 23. pii: 1078-0432.CCR-18-0613.
    PubMed     Text format     Abstract available


  72. BAYRAKTAR R, Ivan C, Bayraktar E, Kanlikilicer P, et al
    Dual suppressive effect of microRNA-34a on the FOXM1/eEF2-kinase axis regulates triple-negative breast cancer growth and invasion.
    Clin Cancer Res. 2018 May 10. pii: 1078-0432.CCR-17-1959.
    PubMed     Text format     Abstract available


    April 2018
  73. SPRING L, Bardia A
    Cycling Towards Progress: Ribociclib, CDK 4/6 inhibitor for Breast Cancer.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-18-0463.
    PubMed     Text format     Abstract available


  74. VISSER LL, Elshof LE, Schaapveld M, Van de Vijver K, et al
    Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ - A nested case-control study.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-18-0201.
    PubMed     Text format     Abstract available


  75. GOODMAN CR, Seagle BL, Kocherginsky M, Donnelly ED, et al
    21-gene recurrence score assay predicts benefit of post-mastectomy radiotherapy in T1-2 N1 breast cancer.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3169.
    PubMed     Text format     Abstract available


  76. POST AEM, Smid M, Nagelkerke A, Martens JWM, et al
    Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer.
    Clin Cancer Res. 2018 Apr 16. pii: 1078-0432.CCR-17-2551.
    PubMed     Text format     Abstract available


  77. WEST DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, et al
    Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer.
    Clin Cancer Res. 2018 Apr 10. pii: 1078-0432.CCR-17-2793.
    PubMed     Text format     Abstract available


  78. LOIBL S, Weber K, Huober J, Krappmann K, et al
    Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinico-molecular predictor.
    Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-2947.
    PubMed     Text format     Abstract available


  79. RUGO HS, Cortes J, Awada A, O'Shaughnessey J, et al
    Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol.
    Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-3059.
    PubMed     Text format     Abstract available


    March 2018
  80. AFGHAHI A, Purington N, Han SS, Desai M, et al
    Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
    Clin Cancer Res. 2018 Mar 26. pii: 1078-0432.CCR-17-1323.
    PubMed     Text format     Abstract available


  81. WARD E, Vareslija D, Charmsaz S, Fagan A, et al
    Epigenome-wide SRC-1 mediated gene silencing represses cellular differentiation in advanced breast cancer.
    Clin Cancer Res. 2018 Mar 22. pii: 1078-0432.CCR-17-2615.
    PubMed     Text format     Abstract available


  82. RUGO HS, Delord JP, Im SA, Ott PA, et al
    Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen ReceptorPositive/Human Epidermal Growth Factor Receptor 2Negative Advanced Breast Cancer.
    Clin Cancer Res. 2018 Mar 20. pii: 1078-0432.CCR-17-3452.
    PubMed     Text format     Abstract available


  83. CHUMSRI S, Sperinde J, Liu H, Gligorov J, et al
    High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-1864.
    PubMed     Text format     Abstract available


  84. FILIPITS M, Dafni U, Gnant M, Polydoropoulou V, et al
    Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: a TransHERA study.
    Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-3473.
    PubMed     Text format     Abstract available


  85. SINGH H, Walker AJ, Amiri-Kordestani L, Cheng J, et al
    U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer.
    Clin Cancer Res. 2018 Mar 9. pii: 1078-0432.CCR-17-3628.
    PubMed     Text format     Abstract available


  86. RICCIARDELLI C, Bianco-Miotto T, Jindal S, Butler LM, et al
    The Magnitude of Androgen Receptor Positivity in Breast Cancer is Critical for Reliable Prediction of Disease Outcome.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-1199.
    PubMed     Text format     Abstract available


  87. LIU L, Yang L, Yan W, Zhai J, et al
    Chemotherapy induces breast cancer stemness in association with dysregulated monocytosis.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-2545.
    PubMed     Text format     Abstract available


    February 2018
  88. FORMENTI SC, Lee P, Adams S, Goldberg JD, et al
    Focal Irradiation And Systemic Transforming Growth Factor beta Blockade in Metastatic Breast Cancer.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-3322.
    PubMed     Text format     Abstract available


  89. NEVEN P, Jongen L, Lintermans A, Van Asten K, et al
    Tamoxifen metabolism and efficacy in breast cancer- a prospective multicentre trial.
    Clin Cancer Res. 2018 Feb 19. pii: 1078-0432.CCR-17-3028.
    PubMed     Text format     Abstract available


  90. KARAPANAGIOTIS S, Pharoah PDP, Jackson CH, Newcombe PJ, et al
    Development and External Validation of Prediction Models for 10-Year Survival of Invasive Breast Cancer. Comparison with PREDICT and CancerMath.
    Clin Cancer Res. 2018 Feb 14. pii: 1078-0432.CCR-17-3542.
    PubMed     Text format     Abstract available


  91. HAMILTON EP, Patel MR, Armstrong AC, Baird RD, et al
    A first in human study of the new oral selective estrogen receptor degrader AZD9496 for HR+/HER2- advanced breast cancer.
    Clin Cancer Res. 2018 Feb 13. pii: 1078-0432.CCR-17-3102.
    PubMed     Text format     Abstract available


  92. SHAH A, Bloomquist E, Tang S, Fu W, et al
    FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-2369.
    PubMed     Text format     Abstract available


  93. KABRAJI S, Ni J, Lin N, Xie S, et al
    Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3351.
    PubMed     Text format     Abstract available


  94. MARTINS CD, Da Pieve C, Burley TA, Smith R, et al
    HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-based PET Imaging.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2754.
    PubMed     Text format     Abstract available


  95. GONG C, Man EP, Tsoi H, Lee TK, et al
    BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen Resistant Breast Cancer.
    Clin Cancer Res. 2018 Feb 2. pii: 1078-0432.CCR-17-2259.
    PubMed     Text format     Abstract available


    January 2018
  96. MISHRA RR, Belder N, Ansari SA, Kayhan M, et al
    Re-activation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer.
    Clin Cancer Res. 2018 Jan 31. pii: 1078-0432.CCR-17-2776.
    PubMed     Text format     Abstract available


  97. ECHAVARRIA I, Lopez-Tarruella S, Picornell AC, Garcia-Saenz JA, et al
    Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.
    Clin Cancer Res. 2018 Jan 29. pii: 1078-0432.CCR-17-1912.
    PubMed     Text format     Abstract available


  98. PIGGOTT L, da Silva AM, Robinson T, Santiago-Gomez A, et al
    Acquired resistance of ER- positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP.
    Clin Cancer Res. 2018 Jan 23. pii: 1078-0432.CCR-17-1381.
    PubMed     Text format     Abstract available


  99. YANG X, Pan Y, Qiu Z, Du Z, et al
    RNF126 as a biomarker of a poor prognosis in invasive breast cancer and CHK1 inhibitor efficacy in breast cancer cells.
    Clin Cancer Res. 2018 Jan 11. pii: 1078-0432.CCR-17-2242.
    PubMed     Text format     Abstract available


  100. MAGBANUA MJM, Rugo HS, Wolfe DM, Hauranieh L, et al
    Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.
    Clin Cancer Res. 2018 Jan 8. pii: 1078-0432.CCR-17-2312.
    PubMed     Text format     Abstract available


  101. DAVILA-GONZALEZ D, Choi DS, Rosato RR, Granados-Principal S, et al
    Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple negative breast cancer.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1437.
    PubMed     Text format     Abstract available


    December 2017
  102. MASTORAKI S, Strati A, Tzanikou E, Chimonidou M, et al
    ESR1 methylation: a liquid biopsy-based epigenetic assay for the follow up of patients with metastatic breast cancer receiving endocrine treatment.
    Clin Cancer Res. 2017 Dec 28. pii: 1078-0432.CCR-17-1181.
    PubMed     Text format     Abstract available


  103. ZHAO EY, Shen Y, Pleasance E, Kasaian K, et al
    Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    Clin Cancer Res. 2017;23:7521-7530.
    PubMed     Text format     Abstract available


    November 2017
  104. LENZ G, Hamilton A, Geng S, Hong T, et al
    t-Darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-0824.
    PubMed     Text format     Abstract available


  105. ROSSI G, Mu Z, Rademaker A, Austin L, et al
    Cell-Free DNA and Circulating Tumor Cells: Comprehensive liquid biopsy analysis in Advanced Breast Cancer.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2092.
    PubMed     Text format     Abstract available


  106. AUSHEV VN, Lee E, Zhu J, Gopalakrishnan K, et al
    Novel predictors of breast cancer survival derived from miRNA activity analysis.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0996.2017.
    PubMed     Text format     Abstract available


  107. EVANS KW, Yuca E, Akcakanat A, Scott SM, et al
    A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    Clin Cancer Res. 2017;23:6468-6477.
    PubMed     Text format     Abstract available


    October 2017
  108. HSU PY, Wu VS, Kanaya N, Petrossian K, et al
    Dual mTOR Kinases MLN0128 Inhibitor Sensitizes HR+/HER2+ Breast Cancer Patient-derived Xenografts to Trastuzumab or Fulvestrant.
    Clin Cancer Res. 2017 Oct 27. pii: clincanres.1983.2017.
    PubMed     Text format     Abstract available


  109. PRICEMAN SJ, Tilakawardane D, Jeang B, Murad JP, et al
    Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2041.2017.
    PubMed     Text format     Abstract available


  110. YU Z, He S, Wang D, Patel HK, et al
    Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor Positive Breast Cancer Models with a Distinct Mechanism of Action.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.0670.2017.
    PubMed     Text format     Abstract available


    September 2017
  111. LUNDBERG A, Lindstrom LS, Harrell JC, Falato C, et al
    Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.1535.2017.
    PubMed     Text format     Abstract available


  112. TOBIN NP, Lundberg A, Lindstrom LS, Harrell JC, et al
    PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.2301.2017.
    PubMed     Text format     Abstract available


  113. DOOSTAN I, Karakas C, Kohansal M, Low KH, et al
    Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
    Clin Cancer Res. 2017 Sep 25. pii: clincanres.1544.2017.
    PubMed     Text format     Abstract available


  114. ZHANG Y, Schroeder BE, Jerevall PL, Ly A, et al
    A novel Breast Cancer Index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1688.2017.
    PubMed     Text format     Abstract available


  115. DIOT G, Metz S, Noske A, Liapis E, et al
    Multi-Spectral Optoacoustic Tomography (MSOT) of human breast cancer.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.3200.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: